DXB
Dimerix Limited
🇦🇺 ASX
🧬 BIOTECHNOLOGY
📈 HIGH PRICE GROWTH
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
+ 42.58%
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
21
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Dimerix Ltd. engages in the investment of the research and development of biopharmaceutical drugs. The company is headquartered in Melbourne, Victoria. The firm is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. The company develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The firm is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets.
📈 Performance
Price History
+6265.66%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.48
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in DXB
21
📊 Total Capital Earnings
$53K
🔃 Average investment frequency
40 weeks
💵 Average investment amount
$1,271
⏰ Last time a customer invested in DXB
5 days
DXB investor breakdown
💵 Income of investors
More than 200k
150k - 200k
9%
100k - 150k
26%
50k - 100k
30%
Less than 50k
30%
👶 Age of investors
18 - 25
10%
26 - 34
38%
35 - 90
52%
🙋 Legal gender of investors
Female
33%
Male
67%
Pearlers who invest in DXB also invest in...
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
3.32%
📊 Share price
$69.46 AUD
🌏 GLOBAL
⛳️ DIVERSIFIED
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
3.16%
📊 Share price
$102.64 AUD
🇦🇺 AUSTRALIA
💸 FINANCIALS
🧱 MATERIALS
⛳️ DIVERSIFIED
IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
17.87%
📊 Share price
$63.18 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The firm is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The firm has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.
🙌 Performance (5Yr p.a)
87.31%
📊 Share price
$13.95 AUD
📦 LOGISTICS
HACK.AX was created on 2016-08-30 by BetaShares. The fund's investment portfolio concentrates primarily on theme equity. The fund aims to track the performance of an index (before fees and expenses) that provides exposure to the leading companies in the global cybersecurity sector.
🙌 Performance (5Yr p.a)
16.38%
📊 Share price
$14.57 AUD
🇦🇺 EX AUSTRALIA
🤖 TECHNOLOGY
📈 HIGH PRICE GROWTH
Want more shares? Try these...
